Thomas Evans

Dr Evans received his MD from the University of Virginia and trained in Internal Medicine at UCSF, and in Infectious Diseases back at Virginia. He established a laboratory during his first position at the University of Utah and directed the HIV clinic.  He moved to the University of Rochester as Associate Professor for 5 years, before becoming Infectious Diseases Division Chief and tenured full Professor at the University of California, Davis. His academic research centered on leishmania and vaccine development and led to him joining Vical, a DNA vaccine developer as Chief Medical Officer in 2002. In 2005 he joined the Novartis Institutes for Biomedical Research as Global Head of Infectious Diseases Translational Medicine and Research. In September 2008 he moved to Shanghai as VP for Translational Sciences in Asia for Novartis. In September 2010 he joined Aeras, a non-profit Product Development Partnership with a mission to develop global tuberculosis vaccines, as the Chief Scientific Officer. He became CEO of Aeras in February 2013. In 2016 he joined TomegaVax as the acting CMO, until acquisition of that company by Vir Biotechnologies. In May 2017 he became CEO of Vaccitech, a spin-off from the Jenner Institute of Oxford University. He has over 150 authored publications.